Innate immune therapy for cancer. Screen for molecules capable of activating the innate immune system

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• Tumor cells express unique antigens, yet the host immune system often fails to mount an effective anti-tumor response.
• Adjuvants, such as Bacillus Calmette-Guerin cell wall skeleton (BCG-CWS), can promote cancer regression in patients.
• Current understanding suggests adjuvants primarily activate innate immunity, specifically antigen-presenting cells, rather than lymphocytes.

Purpose of the Study:

• To investigate the mechanism by which adjuvants enhance anti-tumor immune responses.
• To test the hypothesis that adjuvants create optimal conditions for antigen presentation, overcoming immune unresponsiveness to tumors.
• To establish the potential of innate immune therapy using adjuvants for cancer treatment.

Main Methods:

• Supplementation of cancer patients with adjuvants (e.g., BCG-CWS).
• Assessment of adjuvant effects on antigen-presenting cells, including up-regulation of MHC and co-stimulators.
• Evaluation of the induction of potent immune responses against tumors following adjuvant therapy.

Main Results:

• Adjuvants promote the up-regulation of MHC, co-stimulators, and cytokines in antigen-presenting cells.
• The study provides evidence that adjuvants facilitate antigen presentation, crucial for initiating immune responses.
• The findings support the development of innate immune therapy for cancer patients.

Conclusions:

• Adjuvant therapy is a promising strategy for enhancing the host immune response against tumors.
• Optimizing antigen presentation through adjuvant supplementation can overcome immune tolerance to cancer.
• Innate immune therapy represents a viable approach for treating cancer patients by boosting anti-tumor immunity.